A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.

Phase 3

Sage Therapeutics